Effects of Propionyl-Carnitine in Patients with Type 2 Diabetes and Peripheral Vascular DiseaseResults of a Pilot Trial
作者:
Giovanni Ragozzino,
Edi Mattera,
Elisa Madrid,
Patrizia Salomone,
Carmela Fasano,
Filomena Gioia,
Giusy Acerra,
Raffaele del Guercio,
Pasquale Federico,
期刊:
Drugs in R & D
(ADIS Available online 2004)
卷期:
Volume 5,
issue 4
页码: 185-190
ISSN:1174-5886
年代: 2004
出版商: ADIS
关键词: Anti ischaemics, pharmacodynamics;Propionyl carnitine, pharmacodynamics;Diabetes mellitus;Peripheral vascular disorders
数据来源: ADIS
摘要:
ObjectiveTo assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD).Patients and methodsThis was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 ± 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1).ResultsTreatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported.ConclusionsThis study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.
点击下载:
PDF
(195KB)
返 回